Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic SynchroMed

This article was originally published in The Gray Sheet

Executive Summary

UK MHRA alert cites five instances of the implantable drug pump malfunctioning following use with diamorphine. While the firm stresses that such use is off-label, the healthcare agency notes the drug was omitted from an updated list of incompatible medications provided by the company last October. Medtronic plans to update the UK list to include diamorphine, which is banned in the U.S. MHRA released a similar alert following the initial pump "Educational Brief," citing inclusion of pump-compatible medications not approved for intrathecal use, as well as other additives that could damage the device (1"The Gray Sheet" Nov. 11, 2002, p. 12) ...

You may also be interested in...



UK Device Alert Faults Medtronic SynchroMed Supplemental Drug Labeling

Medtronic's SynchroMed implantable drug pump poses medication error risk due to an inaccurate listing of intrathecal drugs, an Oct. 31 device alert by the UK's Medical Devices Agency indicates

Agios’ Phase III Data Move It Closer To First Therapy For Rare Anemia

Strong top-line efficacy in pyruvate kinase deficiency patients who don’t receive regular transfusions looks approvable, analysts say, but Agios will await data in regularly transfused patients.

US Payers Rate ICER Assessment Updates Using Real World Data As Potentially ‘High Impact’

ICON survey finds payers increasingly use ICER reports at multiple ‘touchpoints’ during the drug evaluation and decision-making process and the most common use reported in 2020 was as a reference in rebate and pricing negotiations.

UsernamePublicRestriction

Register

LL1132440

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel